下一代疫苗辅助剂的合理设计:从分子机制到混合输送平台
Yaping Zhao1, Jie Li2, Jinbai Chen1
1Department of Pharmacy, Shaoxing Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Shaoxing, China.
Human vaccines & immunotherapeutics
|March 16, 2026
概括
本综述探讨了疫苗辅助剂研究中的分子创新,重点是理性设计和天然产品衍生化合物. 了解结构-活性关系 (SAR) 和模式识别受体 (PRR) 向是有效疫苗开发的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 分子生物学分子生物学
背景情况:
- 疫苗辅助剂研究已经从实证配方演变为理性,分子驱动的设计.
- 了解辅助机制对于提高疫苗疗效和指导免疫反应至关重要.
研究的目的:
- 为疫苗辅助剂研究中的分子创新提供全面的分析.
- 分类和评估新兴辅助药类及其作用机制.
- 讨论用于特定临床应用的辅助剂的合理选择.
主要方法:
- 实验辅助剂类别的系统审查和分类.
- 分析天然产品衍生的辅助剂的结构-活性关系 (SAR).
- 分子机制的剖析,包括模式识别受体 (PRR) 向和免疫细胞调制.
主要成果:
- 确定了关键辅助剂类:基于细胞因子,颗粒物递送系统,乳液和基于核酸的策略.
- 通过SAR突出了天然产品衍生的辅助剂的免疫调节潜力.
- 详细介绍了辅助剂如何协调树突细胞成熟,抗原交叉呈现和T辅助细胞两极化.
结论:
- 理性设计原则正在推动疫苗辅助剂的开发.
- 了解分子机制,特别是PRR相互作用,对于辅助剂选择至关重要.
- 未来的战略可能包括结合免疫刺激剂和输送载体的协同多模式方法.
更多相关视频
06:02Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
Published on: February 23, 2024
1.3K
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10.8K
相关概念视频
Vaccinations
53.3K
Overview
53.3K
Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
82
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82
Hybridoma Technology
18.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.2K
